Organization
Celgene Corp.
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Celgene Corp.
... Celgene Corporation (NASDAQ: CELG) today announced primary endpoint findings and updated results of secondary ...
... Novo Nordisk following its strong recovery and the cash was reinvested in Celgene during a significant sell-off in late October. In the smaller and mid ...
... A buyout of Juno Therapeutics could help Celgene diversify its drug portfolio as its No. 1 cancer treatment, which accounts ...
... blood cells, while in the second, they bind to liver cells. RELATED: Celgene splashes out $300M on Delinia autoimmune biotech buy In addition to his ...
... Therapeutics shot up 51.9% to $69.25 after a report that biotech drugmaker Celgene might buy it. Juno is one of several companies developing therapies that ...
... available for free. (Fortune) INDICATIONS Juno shares fly to the moon on Celgene speculation. Juno Therapeutics' stock shot up a whopping 53% in Wednesday trading ...
... Juno Therapeutics surged 51% premarket following a Wall Street Journal report that Celgene is in talks to buy the biotechnology company. Celgene shares were down ...
... Celgene CELG -2.38% is on a shopping spree to fill a looming revenue ...
... up $23.65 to $69.25 The Wall Street Journal reported that biotech drugmaker Celgene may buy the cancer therapy company. Ford Motor Co., down 92 cents ...
... soared 50.9 percent after the Wall Street Journal reported that biotech drugmaker Celgene might buy it. Juno is one of several companies developing therapies that ...
... soared 47 percent after the Wall Street Journal reported that biotech drugmaker Celgene might buy it. The Standard & Poor's 500 index rose 13 points, ...
... deal for Impact Biomedicines at the J.P. Morgan Healthcare Conference last week, Celgene is lining up another deal for CAR-T biotech Juno Therapeutics, according to ...
... soared 46.5 percent after the Wall Street Journal reported that biotech drugmaker Celgene might buy it. Juno is one of several companies developing therapies that ...
... Celgene is in talks to buy biotechnology company Juno Therapeutics, The Wall Street ...
... Celgene Corp. is in talks to buy biotechnology company Juno Therapeutics Inc., just ...
... Celgene is looking to buy yet another biotech company. The Summit, New Jersey-based ...
... paclitaxel), REVLIMID® (lenalidomide), and VIDAZA® (azacitidine) in China under a license from Celgene Corporation.1 Forward-Looking Statements Certain of the statements made in this press release ...
... and licensing. They include some of the industry's most recognizable names (AstraZeneca, Celgene, and Merck) and life sciences upstarts like Rigontec, CureVac, and IFM Therapeutics. ...
... bill sets the stage for major M&A activity. Execs from Eli Lilly, Celgene, Medtronic, and Vertex all expressed their pleasure with the new tax bill. ...
... attributed to increase in patent expirations. For instance, the R&D expenditure of Celgene Corporation increased from USD 3,697.3 million in 2015 to USD 4,470.1 million ...
... rs Celgene Celgene chief Alles discusses deal to acquire Impact Biomedicines, strategy for 2018 ...
... healthcare expenditure. Some of the key players in Global Epigenetics market are Celgene Corporation, CellCentric Ltd, Chroma Therapeutics Ltd, Covaris Inc, DIAGENODE, INC., Ribimed Biotechnologies, ...
... late in the year, given the hurdles still facing Incyte. 4. Ozanimod; Celgene: $979 million Designed for multiple sclerosis patients, this drug curtails the inflammatory ...
... kicking off with a deal worth $7 billion and from big biotech Celgene, no less—although much of this was back-loaded, with just over a billion ...
... a broad array of both solid tumor and hematologic cancers. BeiGene and Celgene Corporation have a global strategic collaboration for tislelizumab for solid tumors outside ...
... Celgene Corp. agreed to buy San Diego firm Impact Biomedicines for $1.1 billion ...
Want to see the full history on Celgene Corp.? Upgrade to RelSci Pro now!
Start My Free Trial